Discover more insights into Oncology Trials

Keywords frequently search together with Oncology Trials

Narrow sentence examples with built-in keyword filters

Oncology Trials sentence examples within maximum tolerated dose



Keyboard: An R Package Suite for Early Phase Dose-finding Designs



Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.


Oncology Trials sentence examples within Precision Oncology Trials



TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials



Racial and ethnic disparities among participants in precision oncology clinical studies.


Oncology Trials sentence examples within I Oncology Trials



A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials



Bridging across patient subgroups in phase I oncology trials that incorporate animal data




Oncology Trials sentence examples within Ius Oncology Trials



Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials.



A new basket trial design based on clustering of homogeneous subpopulations


Oncology Trials sentence examples within Clinical Oncology Trials



CHK yourself, before you wreck yourself: targeting the DNA damage response in secondary pulmonary hypertension



Targeting Parthanatos in Ischemic Stroke


Oncology Trials sentence examples within Iius Oncology Trials



Cancer patient survival can be accurately parameterized, revealing time-dependent therapeutic effects and doubling the precision of small trials



A survival mediation model with Bayesian model averaging.


Oncology Trials sentence examples within Phase Oncology Trials



SPA: Single patient acceleration in oncology dose-escalation trials.



The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ


Oncology Trials sentence examples within Pediatric Oncology Trials



Do the Potential Medical Benefits of Phase 1 Pediatric Oncology Trials Justify the Risks? Views of the US Public.



Patient Reported Outcomes in Pediatric Cancer Registration Trials: A U.S. Food and Drug Administration Perspective.


Oncology Trials sentence examples within Nrg Oncology Trials



Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.



Final Report of NRG Oncology RTOG 0022: A Phase I/II Study of Conformal and Intensity Modulated Radiation for Oropharyngeal Cancer.


Oncology Trials sentence examples within Adult Oncology Trials



Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.



Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols


Oncology Trials sentence examples within 1 Oncology Trials



Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma



Participation of women in phase I oncology clinical trials


Oncology Trials sentence examples within Two Oncology Trials



A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data.



Commentary on Hay et al.: Can clinical trials data collection be improved by administrative data elements?


Oncology Trials sentence examples within Surgical Oncology Trials



The surgical oncology clinical trial landscape: A cross-sectional analysis of ClinicalTrials.gov from 2008-2020.



Challenging traditional research: A synopsis of the National Research Collaborative Meeting (NRCM) in 2017


Oncology Trials sentence examples within Finding Oncology Trials



Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials.gov.



Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials


Oncology Trials sentence examples within Pivotal Oncology Trials



Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors



Subgroup analyses in oncology trials: regulatory considerations and case examples.


Oncology Trials sentence examples within oncology trials registered



Female participation in U.S. oncology clinical trials registered on ClinicalTrials.gov from 2008 to 2020.



Evaluation of Oncology Trial Results Reporting Over a 10-Year Period


Oncology Trials sentence examples within oncology trials often



Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials.



Abstract 1433: NeoTCR-P1, a novel neoepitope-specific adoptive cell therapy, consists of T cells with ‘younger’ phenotypes that rapidly proliferate and kill target cells upon recognition of cognate antigen


Oncology Trials sentence examples within oncology trials need



Personalizing Precision Oncology Clinical Trials in Latin America: An Expert Panel on Challenges and Opportunities.



Optimizing access to matched therapies


More Oncology Trials sentence examples
10.1186/s12967-020-02627-y

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)


More Oncology Trials sentence examples
10.1200/jco.2020.39.28_suppl.85

Female participation in U.S. oncology clinical trials registered on ClinicalTrials.gov from 2008 to 2020.



Pragmatic patient engagement in designing pragmatic oncology clinical trials.


More Oncology Trials sentence examples
10.6004/jnccn.2021.7015

Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials.


More Oncology Trials sentence examples
10.2174/1574887116666210713141235

An Audit of Interim Analyses of Randomized Controlled Trials [RCTs] Published in Three High Impact Factor Medical Journals over a seven-year period [2012-2018].


More Oncology Trials sentence examples
10.1016/j.critrevonc.2021.103350

Critical Review of Oncology Clinical Trial Design Under Non-proportional Hazards.



Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.


More Oncology Trials sentence examples
10.1093/med/9780198821328.003.0011

Specialist palliative care along the trajectory of illness


More Oncology Trials sentence examples
10.1016/j.ijrobp.2021.07.628

Cardiotoxicity as an Endpoint in Prospective Clinical Trials Involving Chest Radiation Therapy.



A Bayesian approach for event predictions in clinical trials with time-to-event outcomes.


More Oncology Trials sentence examples
10.6004/jadpro.2021.12.6.2

Disparities and Access to Care: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner


More Oncology Trials sentence examples
10.1007/s11523-021-00837-y

Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)


More Oncology Trials sentence examples
10.46883/ONC.2021.3503.0107

Minority Enrollment to Clinical Trials: Road to Increased Access.


More Oncology Trials sentence examples
10.1136/bmjopen-2020-047294

Importance and role of independent data monitoring committees (IDMCs) in oncology clinical trials



Practical and robust test for comparing binomial proportions in the randomized phase II setting.


More Oncology Trials sentence examples
10.1007/s11136-021-02945-8

Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review


More Oncology Trials sentence examples
10.3389/fimmu.2021.736943

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer


More Oncology Trials sentence examples
10.1200/JCO.2021.39.15_SUPPL.E18587

Landscape review of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in oncology: Adoption and recent learnings.


More Oncology Trials sentence examples
10.1007/s43441-021-00335-3

Historical Benchmarks for Quality Tolerance Limits Parameters in Clinical Trials



Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?



Editorial: Reporting Clinical Trials with Important Modifications Due to Extenuating Circumstances, Including the COVID-19 Pandemic: CONSERVE 2021



Validation of the Korean Version of the Patient-Reported Outcomes Measurement Information System 29 Profile V2.1 among Cancer Survivors.


More Oncology Trials sentence examples
10.1200/JCO.2021.39.15_SUPPL.E18516

Racial distribution of clinical trial participants in the United States.



[Routine Practice Data for Evaluating Intervention Effects: Part 2 of the Manual].


More Oncology Trials sentence examples
10.1038/s41408-021-00543-y

Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement


More Oncology Trials sentence examples
10.1016/j.conctc.2019.100446

Minimizing control group allocation in randomized trials using dynamic borrowing of external control data – An application to second line therapy for non-small cell lung cancer



Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed.


More Oncology Trials sentence examples
10.1093/rheumatology/kez297

Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy



What Drug Development Sponsors, Contract Research Organizations, and Investigators Can Do to Increase Diversity in Clinical Trials



Critical appraisal of clinical trials in oncology — part I


More Oncology Trials sentence examples
10.1158/1538-7445.AM2019-1433

Abstract 1433: NeoTCR-P1, a novel neoepitope-specific adoptive cell therapy, consists of T cells with ‘younger’ phenotypes that rapidly proliferate and kill target cells upon recognition of cognate antigen



Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End‐Stage Renal Disease on Maintenance Hemodialysis


More Oncology Trials sentence examples
10.1016/j.jaccao.2019.08.007

The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity.


More Oncology Trials sentence examples
10.1245/s10434-019-07920-9

ASO Author Reflections: Patient-Reported Outcomes—Bench to Bedside


More Oncology Trials sentence examples
10.1038/s41416-019-0532-4

Challenges of international oncology trial collaboration—a call to action



Mapping child and adolescent self‐reported symptom data to clinician‐reported adverse event grading to improve pediatric oncology care and research


More Oncology Trials sentence examples
10.1007/978-3-030-01207-6_5

Patient-Reported Outcomes in Oncology, Beyond Randomized Controlled Trials.


More Oncology Trials sentence examples
10.1016/j.jclinepi.2019.11.018

The Clinical trial transparency in oncology significantly increased over the recent years.


More Oncology Trials sentence examples
10.1093/annonc/mdz244.048

Analysis of the overall survival and main surrogates used for FDA approvals in solid and haematological malignancies


More Oncology Trials sentence examples
10.1158/1538-7445.SABCS18-GS2-07

Abstract GS2-07: PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer


More Oncology Trials sentence examples
10.1200/JCO.2019.37.15_SUPPL.E23171

Utilizing the patient-reported outcomes measurement information system (PROMIS) to assess quality of life among breast cancer patients at an academic center.


More Oncology Trials sentence examples
10.1007/s00520-019-04677-5

Examining the “usual” in usual care: a critical review and recommendations for usual care conditions in psycho-oncology


More Oncology Trials sentence examples
10.1097/RTI.0000000000000390

Measurement Variability in Treatment Response Determination for Non-Small Cell Lung Cancer: Improvements Using Radiomics.


Learn more from Oncology Trials


Oncology Trials
Encyclopedia